NCT05022186

The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

Comparative Randomized Clinical Trial of the Efficacy of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment and APOE ε4 Carriers

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Aristotle University Of Thessaloniki · Academic / Other
• Sex: All
• Age: 65 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers. Ninety patients will be recruited and they will be randomly distributed in three groups. The first group will receive treatment with Cannabidiol 5%, the second group will receive treatment with Vivimind and the third group will not receive any treatment. The three groups will be compared by using an extensive neuropsychological examination and biomarkers' results from cerebrospinal fluid and blood

Conditions

• Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	Cannabidiol Oil	Patients will use it with specific instructions and they will be monitored at least one time in a month
DRUG	Homotaurine	Patients will use it with specific instructions and they will be monitored at least one time in a month

Timeline

• Start date: 2021-04-01
• Primary completion: 2022-12-20
• Completion: 2022-12-20
• First posted: 2021-08-26
• Last updated: 2021-08-26

Locations

1 site across 1 country: Greece